BioInformatics LLC New Market Report - The 2012 Antibodies Market

March 13, 2012 |

2 min read

ARLINGTON, VA, March 13, 2012 – BioInformatics LLC announces the release of their newest market report: The 2012 Antibodies Market (12-001) This worldwide primary research study of the academic and pharma/biotech sectors provides a comprehensive analysis of the market for commercial, pre-made catalog antibodies. The report provides an in-depth exploration of scientists’ expectations and preferences with regards to usage, brands, purchasing, product quality and budgets. Key findings highlight market share, competitive positioning, customer satisfaction and how well current products meet researchers’ needs. The following is a sample of some of the suppliers who were provided as answer choices in the survey:

- Abcam

- AbD Serotec (MorphoSys)

- Active Motif

- Amersham (GE Healthcare) (NYSE: GE)

- BD Pharmingen (BD Biosciences) (NYSE:BDX)

- Beckman Coulter (NYSE:BEC)

- Cell Signaling Technology

- Covance (NYSE:CVD)

- Dako

- Invitrogen (Life Technologies) (NasdaqGS: LIFE)

- Jackson ImmunoResearch Laboratories

- KPL (Kirkegaard & Perry Laboratories)

- Miltenyi Biotec

- Novus Biologicals

- Pierce (Thermo Fisher Scientific) (NYSE: TMO)

- Promega

- R&D Systems

- Roche Applied Science

- Santa Cruz Biotechnology

- Sigma-Aldrich (NasdaqGS: SIAL)

- Upstate (EMD Millipore/Merck Millipore)

“The sheer numbers of antibodies suppliers makes this market unique,” states Tamara Zemlo, Ph.D., MPH, Vice President of Advisory Services.

Dr. Zemlo adds that: “The market analysis presented in this report will provide life science suppliers with the guidance they need to be competitive in a crowded space.”

To learn more about this report, a complimentary Executive Summary is available at: http://www.gene2drug.com/index.php?page=reports&id=223

ABOUT BIOINFORMATICS LLC

BioInformatics LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 69,000 life scientists, we have supported more than 500 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.

For more information contact:

Mary Follin Manager, Marketing/Sales BioInformatics LLC 703.778.3080 x13 (phone) m.follin@gene2drug.com

http://www.gene2drug.com/